[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551958":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":54,"collaborators":41,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":41,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":41,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":41,"overallStatus":39,"whyStopped":41,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Isfahan University of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Patients with moderate to severe osteoarthritis, Kellgren-Lawrence grade 2,3 in both knees; accompanied by mild to moderate pain and swelling are included.",[13],"Biological: Exosome",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Exosome","intra-articular injection is suggested for two times: day 1and day 90",[9],[21],"EVs",[23],{"name":24,"affiliation":5,"role":25},"Leila Dehghani, Dr","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","36202020","031","l_dehghani2002@yahoo.com",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Masoud Soleimani, Prof","03136202020","a70.leiladehghani@gmail.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Leila Dehghani","RECRUITING","Isfahan",null,"Iran","IR",{"type":45,"coordinates":46},"Point",[47,48],51.67462,32.65246,{"lat":48,"lon":47},[51,53],{"name":52,"role":28,"phone":29,"phoneExt":30,"email":31},"Leila Dehghani, Assisstant Prof",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":35},{"type":25,"investigatorFullName":38,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Dr","100551958","mesenchymal-stem-cells-derived-exosomes-in-osteoarthritis-patients-100551958",false,"NCT06466850","Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","Inclusion Criteria:\n\n* Chronic history (for at least 3 months) of knee joint pain\n* Body mass index (BMI) between 21.5 and 29.5\n* Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)\n\nExclusion Criteria:\n\n* Rheumatoid arthritis and other rheumatic diseases\n* Varus or valgus more than 10 degrees; lateral subluxation of the patella\n* Deformity at the joint levels or adjacent to the knee due to fracture or any other injury\n* Complete rupture of the ligament and meniscus leading to laxity or locking\n* Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk\n* Hyaluronic acid infiltration within the previous six months\n* Hemoglobin levels \\\u003C10 g\u002FdL;","ALL","45 Years","75 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71],"NA","Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).\n\nOA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and \"a disintegrin and metalloproteinase with thrombospondin motifs\" (ADAMTS).\n\nMSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.\n\nExosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.\n\nThis research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.",[74],"Osteoarthritis, Knee","2025-09-08",{"date":77,"type":78},"2025-09-15","ACTUAL",{"date":80,"type":78},"2024-01-01",{"date":82,"type":68},"2026-12-25",{"name":5,"class":6},1]